We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Strontium-89 Relieves Bone Pain, May Have Therapeutic Value

Jan 1, 1996
Volume: 
5
Issue: 
1
  • Prostate Cancer

MIAMI BEACH--Cancer patients treated with strontium-89 (Metastron)
for palliation of their metastatic bone pain may also benefit
therapeutically, said Michael J. Katin, MD, a radiation oncologist
in Fort Myers, Florida, whose practice includes a significant
number of patients with painful bone metastases resulting primarily
from prostate cancer.

"Evidence is mounting to suggest that strontium-89 may retard
the progression of metastatic disease," Dr. Katin said at
a symposium on metastatic prostate cancer held in conjunction
with the American Society for Therapeutic Radiology and Oncology
(ASTRO) meeting.

Dr. Katin described the Trans-Canada Study, which tested the efficacy
of strontium-89 adjuvant to local field external beam radiotherapy
in 126 patients with multiple bone mets secondary to hormone-refractory
prostate cancer.

Patients treated with strontium-89 had a larger decrease in new
sites of pain, and significantly more of these patients reported
no newly painful sites, compared with the placebo arm (59% vs
34% for the two groups, respectively). Blood levels of serum tumor
markers were also significantly reduced in patients who received
strontium-89, compared with placebo-treated patients, during the
first 4 months after therapy.

Similar results were seen with the UK Metastron Investigators'
Group study, which compared strontium-89 treatment with external
beam therapy in 305 patients with painful prostatic metastatic
cancer. Significantly fewer patients who received strontium-89
developed new painful sites or needed additional therapy than
did those treated with radiation.

Since 1988, Dr. Katin has used strontium-89 in 229 patients. Overall,
76% had metastatic prostate cancer. Of these, pain decreased in
83% who were treated with a 50 µCi/kg injection; 13% had
total relief of their pain and were able to discontinue their
analgesics.

Dr. Katin emphasized that while he has not systematically examined
the question of whether strontium-89 provides therapeutic benefit,
he is nonetheless convinced that it has this property.

Pages

  • 1
  • 2
  • next ›
  • last »

Related Articles

  • No Improved Outcomes in Prostate Cancer With ADT Plus Mitoxantrone/Prednisone
  • No Benefit in Outcomes With Higher Resource Use in Metastatic Prostate Cancer
  • Proton RT for Prostate Cancer Has Reduced Toxicity, Higher Cost vs Other RT Options
  • ‘Screening Smarter’ for Prostate Cancer
  • Enzalutamide Granted Priority Review for Expanded Use in Prostate Cancer

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.